Hyperadrenocorticism – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hyperadrenocorticism – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Using [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Patients with Cushing’s Disease https://clinicaltrials.eu/trial/study-on-using-18ffet-pet-mri-to-improve-detection-of-pituitary-adenomas-in-patients-with-cushings-disease/ Wed, 29 Apr 2026 15:04:57 +0000 https://clinicaltrials.eu/trial/study-on-using-18ffet-pet-mri-to-improve-detection-of-pituitary-adenomas-in-patients-with-cushings-disease/ This clinical trial is focused on studying a condition known as Cushing’s disease, which is a type of ACTH-dependent hypercortisolism. This condition occurs when the body produces too much of a hormone called cortisol, often due to a small tumor in the pituitary gland. The study will use a special imaging technique called [18F]FET PET-MRI to help detect these tumors more accurately. The treatment involves using a solution for injection that contains a substance called fluoroethyltyrosine F-18, which helps in creating detailed images of the pituitary gland.

The purpose of the study is to see if the [18F]FET PET-MRI method can better identify Cushing’s disease compared to the current standard method, which is a procedure called IPSS (Inferior Petrosal Sinus Sampling). Participants in the study will undergo imaging with the [18F]FET PET-MRI to see if it can correctly differentiate between Cushing’s disease and another condition called ectopic Cushing’s syndrome, where the excess cortisol is produced by tumors located outside the pituitary gland.

Throughout the study, participants will receive the fluoroethyltyrosine F-18 injection and undergo the PET-MRI scan. The results will be compared to those from the IPSS procedure to determine which method is more effective in identifying the source of the excess hormone production. The study aims to improve the accuracy of diagnosing Cushing’s disease, potentially leading to better treatment options for patients with this condition.

]]> Study of SPI-62 for Treating Cushing’s Syndrome in Patients with Benign Adrenal Tumors https://clinicaltrials.eu/trial/study-of-spi-62-for-treating-cushings-syndrome-in-patients-with-benign-adrenal-tumors/ Wed, 29 Apr 2026 14:58:35 +0000 https://clinicaltrials.eu/trial/study-of-spi-62-for-treating-cushings-syndrome-in-patients-with-benign-adrenal-tumors/ This clinical trial is focused on studying a condition known as Hypercortisolism, which is related to a non-cancerous growth in the adrenal gland. The adrenal glands are small organs located on top of the kidneys that produce hormones, including cortisol. In some cases, these glands can produce too much cortisol, leading to hypercortisolism. This condition can cause various health issues, such as high blood sugar, high blood pressure, and weakened bones. The trial will investigate the effects of a new treatment called SPI-62, which is taken as a film-coated tablet.

The purpose of the study is to evaluate the benefits and risks of using SPI-62 in people who have complications due to hypercortisolism. Participants in the study will receive either the new treatment or a placebo. The study will last for a period of up to 78 weeks, during which participants will be monitored for any changes in their condition and any side effects they may experience. The goal is to see if SPI-62 can help manage the symptoms of hypercortisolism and improve the overall health of the participants.

Throughout the study, researchers will collect information on how the treatment affects various symptoms of hypercortisolism, such as high blood sugar, high cholesterol, and high blood pressure. They will also look at the long-term safety of the treatment, focusing on any serious health issues that may arise. This information will help determine if SPI-62 is a safe and effective option for people with hypercortisolism related to benign adrenal tumors.

]]> Study on Metyrapone for Patients with Mild Autonomous Cortisol Secretion https://clinicaltrials.eu/trial/study-on-metyrapone-for-patients-with-mild-autonomous-cortisol-secretion/ Wed, 29 Apr 2026 14:58:01 +0000 https://clinicaltrials.eu/trial/study-on-metyrapone-for-patients-with-mild-autonomous-cortisol-secretion/ This clinical trial is focused on studying a condition known as mild autonomous cortisol secretion, which involves the body producing too much of a hormone called cortisol. The treatment being tested in this study is a medication called Metycor, which contains the active substance metyrapone. Metyrapone works by inhibiting an enzyme in the adrenal gland, which helps reduce the production of cortisol.

The purpose of the study is to assess whether treatment with Metycor can improve certain health conditions related to excess cortisol, such as high blood pressure, issues with blood sugar levels, and overall cortisol levels. Participants in the study will take Metycor for a period of six months. During this time, their health will be monitored to see if there are improvements in these areas.

Throughout the study, participants will have their blood pressure and blood sugar levels checked, and their cortisol levels will be measured. The study will also look at other health factors, such as weight, cholesterol levels, and quality of life. The goal is to determine if Metycor can help manage the symptoms associated with mild autonomous cortisol secretion and improve the overall health of the participants.

]]>